Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
58,106.29 +540.88 (+0.94%) CMC Crypto 200
1,252.18 -18.56 (-1.46%)
REGN May 2024 770.000 call
| Previous close | 200.00 |
| Open | 200.00 |
| Bid | 137.60 |
| Ask | 145.60 |
| Strike | 770.00 |
| Expiry date | 2024-05-17 |
| Day's range | 200.00 - 200.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireRegeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
ZacksWill These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
ZacksShould You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
